Vigil Neuroscience to Present at Upcoming Investor Conferences
November 07, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
November 02, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF...
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
November 01, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference
September 01, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces $75 Million Private Placement Financing
August 12, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment of patients with ALSP – – Prioritizing VGL101 in...
Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022
August 01, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.
July 28, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia
June 07, 2022 07:00 ET
|
Vigil Neuroscience, Inc.
- Received approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 trial of VGL101 in healthy volunteers at doses above 20 mg/kg - - Considering administration of a 30...